NEW YORK (360Dx) – Leo Pharma said today that it has entered a collaboration with Estonia-based FibroTx to assess disease severity and monitor treatment effects in atopic dermatitis patients using a non-invasive skin test technology developed by FibroTx.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.